摘要
[目的]观察瑞宁得治疗绝经后晚期乳腺癌的客观缓解率、出现疾病进展的时间(TTP)及不良反应。[方法]26例初次内分泌治疗或既往曾用三苯氧胺辅助治疗的绝经后晚期乳腺癌患者 ,给予瑞宁得1mg,每天1次 ,直至病情进展或出现不能耐受的不良反应为止。[结果]肿瘤客观缓解率(CR +PR)为19%、稳定(S)为46%、进展(P)为35%。中位缓解期16个月(8～25个月)。临床受益率(CR +PR +S≥24周)为50% ,中位TTP为8个月(2～25个月)。16例患者治疗前后接受了血雌二醇(E2)测定 ,治疗后E2 比治疗前降低了78%。不良反应包括潮热、恶心、呕吐、乏力、体重增加及阴道干燥 ,其发生率分别为19%、15 %、8%、8 %、8%及4% ,均为WHOⅠ度不良反应。[结论]瑞宁得能明显降低血E2 水平 ,是治疗绝经后晚期乳腺癌的有效内分泌药物 ,耐受性好 ,口服剂型 ,使用方便 ,值得临床应用。
To investigate the efficacy,time to progression(TTP)and side effects of Arimidex for treatment of advanced breast cancer in postmenopausal women.Twenty six patients with first line endocrine therapy or prior tamoxifen adjuvant therapy were treated with Arimidex 1mg once a day until appearing disease progression or toxicity intolerable.The objective response rate(CR+PR)was 19% with median duration of response of 16 months(8～25months).Clinical benefit (CR+PR+SD≥24weeks)was 50% and median TTP was 8 months(2～25 months).The plasma oestradiol(E2)was suppressed by 78% in 16 cases tested.The side effects included hot flushes,nausea,vomiting,fatigue,weight gain and vaginal dryness,but all the toxicity were grade Ⅰ of WHO.[Conclusion]Arimidex can obviously reduce plasma E2 level in postmenopausal women.It is an effective endocrine therapy with good tolerance for advanced breast cancer in postmenopausal women.
出处
《肿瘤学杂志》
CAS
2002年第1期7-8,共2页
Journal of Chinese Oncology
